We are live on ! Find out more
VRX

VALEANT PHARMACEUTICALS INTL
VRX

Delisted

VRX was delisted on the 27th of September, 2010.

Back to rankings

3 hedge funds and large institutions have $13M invested in VALEANT PHARMACEUTICALS INTL in 2015 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,536% more capital invested

Capital invested by funds: $797K → $13M (+$12.2M)

200% more funds holding

Funds holding: 1 → 3 (+2)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
+2
Holders Change %
+200%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SAM
Shikiar Asset Management
New York
+$6.97M
2
PIM
Perkins Investment Management
Illinois
+$4.97M

Top Sellers

Rank Fund Capital Flow
1
CG
Colony Group
Massachusetts
-$1.79K
Name Holding Trade Value Shares
Change 		Change in
Stake
SAM
1
Shikiar Asset Management
New York
$6.97M +$6.97M +35,080 New
PIM
2
Perkins Investment Management
Illinois
$4.97M +$4.97M +25,000 New
CG
3
Colony Group
Massachusetts
$1.1M -$1.79K -9 -0.2%

VRX Hedge Fund Activity: Q1 2015 in Review

3 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in VALEANT PHARMACEUTICALS INTL (VRX) for Q1 2015, worth a combined $13M — up 1,536% from $797K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new VRX positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Shikiar Asset Management, opening a new position worth an estimated $6.97M. The largest seller was Colony Group, cutting an estimated $1.79K.

  • 3 institutional investors held VALEANT PHARMACEUTICALS INTL (VRX) as of Q1 2015, up from 1 in Q4 2014.
  • Funds reported $13M of VALEANT PHARMACEUTICALS INTL stock for Q1 2015, up 1,536% quarter-over-quarter.
  • 2 funds opened new VALEANT PHARMACEUTICALS INTL positions in Q1 2015 and 0 closed out, a net change of +2 holders.
  • The largest VALEANT PHARMACEUTICALS INTL buyer in Q1 2015 was Shikiar Asset Management, an estimated $6.97M added.
  • The largest VALEANT PHARMACEUTICALS INTL seller in Q1 2015 was Colony Group, an estimated $1.79K sold.

Based on aggregated 13F filings for Q1 2015.